Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Afraxis Inc.

www.afraxis.com

Latest From Afraxis Inc.

Execs On The Move, June 2013

Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

BioPharmaceutical Medical Device

Start-Up Quarterly Statistics, Q1 2013

Start-up company fundraising got off to a slow start in 2013: life sciences companies brought in $398.7 million, roughly 59% less than in the final quarter of 2012. Of the total raised, 84% went to biopharmas. The majority of start-up alliances were for discovery- or preclinical-stage products and there were four start-up acquisitions for the quarter – three in biopharma and one in the medical device sector.

BioPharmaceutical Medical Device

Venture Firm Avalon Turns To GSK To Share Biotech Risk

Entering its fourth decade, Avalon fights through “dark days” and taps GlaxoSmithKline to help fund its next crop of early-stage start-ups. In exchange, it must deliver assets, not platforms, to trigger a GSK acquisition of those start-ups, with pre-arranged returns.

BioPharmaceutical United States

Deals Shaping The Medical Industry, March 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Afraxis Inc.
  • Senior Management
  • Carmine Stengone, Pres. & CEO
    Christopher Rex, PhD, CSO
  • Contact Info
  • Afraxis Inc.
    Phone: (858) 750-4707
    11099 N. Torrey Pines Rd.
    Ste. 290
    La Jolla, CA 92037
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register